ArticleSchizophrenia bulletin2016
Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.
Article in Schizophrenia bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Mitochondrial Dysfunction and Cognitive Impairment in Schizophrenia: The Role of Inflammation.Schizophrenia bulletin · 2025Pooled it
- Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review.Current neuropharmacology · 2018Pooled it
- Association between TLR2 polymorphisms (- 196-174 Ins/Del, R677W, R753Q, and P631H) and schizophrenia in a Tunisian population.Immunologic research · 2021Trial
- Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis.Acta neuropsychiatrica · 2019Trial
- Silent Inflammation: A Critical Narrative Review of the Relationship Between Periodontal Disease and Psychosis-The Role of Oxidative Stress and Iatrogenic Comorbidities.Antioxidants (Basel, Switzerland) · 2026Review
- Microbiome-Gut-Brain Profiles in Schizophrenia and Their Potential Link to Cognitive Performance: Findings from a Case-Control Study.Schizophrenia bulletin · 2025Article
- Inflammation, childhood trauma, and symptom dimensions in schizophrenia: a path-analysis study.Brain, behavior, & immunity - health · 2025Article
- Relationship Between Family Support, C-Reactive Protein and Body Mass Index Among Outpatients with Schizophrenia.Healthcare (Basel, Switzerland) · 2025Article
- Relationship between pain, functionality, and body composition in patients with fibromyalgia: cross-sectional study.Frontiers in medicine · 2025Article
- Changes in psychopathology and peripheral inflammation in schizophrenia patients initiating treatment with second-generation antipsychotics: a post-hoc analysis.Frontiers in psychiatry · 2025Article
- Cerebrospinal Fluid from Patients After Craniotomy with the Appearance of Interleukin-6 Storm Can Activate Microglia to Damage the Hypothalamic Neurons in Mice.Molecular neurobiology · 2024Article
- Quality of Life and C-Reactive Protein in Patients with Schizophrenia: A Cross-Sectional Study.Alpha psychiatry · 2024Article
- Executive functioning trajectories and their prospective association with inflammatory biomarkers in schizophrenia and non-psychiatric comparison participants.Progress in neuro-psychopharmacology & biological psychiatry · 2024Article
- Clinical and biological correlates of optical coherence tomography findings in schizophrenia.European archives of psychiatry and clinical neuroscience · 2023Article
- The Relationship of Cognitive Dysfunction with Inflammatory Markers and Carotid Intima Media Thickness in Schizophrenia.Journal of personalized medicine · 2023Article
- Cognitive function in recovered COVID-19 Lebanese patients with schizophrenia.Annals of general psychiatry · 2023Article
- Altered mitochondrial lymphocyte in overweight schizophrenia patients treated with atypical antipsychotics and its association with cognitive function.Frontiers in immunology · 2023Article
- C-Reactive Protein (CRP): A Potent Inflammation Biomarker in Psychiatric Disorders.Advances in experimental medicine and biology · 2023Article
- A Comparison of the Relationship Between C-Reactive Protein Levels and Cognitive Functions in Patients with Schizophrenia, First-Episode Psychosis, and Healthy Controls.Psychiatry and clinical psychopharmacology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 15 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesInflammation, measured by abnormal blood C-reactive protein (CRP) level, has been described in schizophrenia (SZ), being inconsistently related to impaired cognitive functions. The aim of the present study is to investigate cognitive impairment associated with abnormal CRP levels in a large multi-centric sample of community-dwelling SZ patients, using a comprehensive neuropsychological battery.
methodThree hundred sixty-nine community-dwelling stable SZ subjects (76.2% men, mean age 32.7 y) were included and tested with a comprehensive battery of neuropsychological tests. Abnormal CRP level was defined as >3mg/L.
resultsMultiple factor analysis revealed that abnormal CRP levels, found in 104 patients (28.2%), were associated with impaired General Intellectual Ability and Abstract Reasoning (aOR = 0.56, 95% CI 0.35-0.90, P = .014), independently of age, sex, education level, psychotic symptomatology, treatments, and addiction comorbidities. Abnormal CRP levels were also associated with the decline of all components of working memory (respectively effect size [ES] = 0.25, P = .033; ES = 0.27, P = .04; ES = 0.33, P = .006; and ES = 0.38, P = .004) and a wide range of other impaired cognitive functions, including memory (ES = 0.26, P = .026), learning abilities (ES = 0.28, P = .035), semantic memory (ES = 0.26, P = .026), mental flexibility (ES = 0.26, P = .044), visual attention (ES = 0.23, P = .004) and speed of processing (ES = 0.23, P = .043).
conclusionOur results suggest that abnormal CRP level is associated with cognitive impairment in SZ. Evaluating the effectiveness of neuroprotective anti-inflammatory strategies is needed in order to prevent cognitive impairment in SZ.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.